Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial

American Heart Journal

Volumn 139, Issue 6, 2000, Pages 927-933

  Topol, Eric J ^a   Donald Easton, J ^b   Amarenco, Pierre ^c   Califf, Robert ^d   Harrington, Robert ^d   Graffagnino, Carmen ^d   Davis, Stephen ^e   Diener, H C ^f   Ferguson, James ^g   Fitzgerald, Desmond ^h   Shuaib, Ashfaq ⁱ   Koudstaal, Peter J ^j   Theroux, Pierre ^k   Van De Werf, Frans ^l   Willerson, James T ^m   Chan, Robert ⁿ   Samuels, Robert ⁿ   Ilson, Bernard ⁿ   Granett, Jeffrey ⁿ  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BROWN UNIVERSITY   (United States)

^c HÔPITAL LARIBOISIÈRE   (France)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g TEXAS HEART INSTITUTE   (United States)

^h ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k MONTREAL HEART INSTITUTE   (Canada)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

ⁿ GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR; LOTRAFIBAN; TICLOPIDINE;

ARTICLE; BLOOD VESSEL OCCLUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION; RISK BENEFIT ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0034120747     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.105107     Document Type: Article

References (20)

1. Turitto VT, Baumgartner HR. Platelet-surface interactions. In: Colman RW, Hirsh J, Marder VJ, et al, editors. Hemostasis and thrombosis, basic principles and clinical practice. Philadelphia: JB Lippincott; 1982. p. 364-79.
2. Fuster VT, Badimon J, Chesebro J. The pathogenesis of coronary artery disease and acute coronary syndromes. N Engl J Med 1992;326:242-50.
3. Antiplatelet Therapy Trialist Collaborators. Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
4. Antiplatelet Therapy Trialist Collaborators. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:159-68.
5. Antiplatelet Therapy Trialist Collaborators. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:235-46.
6. Gent M, Beaumont D, Blanchard J, et al. A randomized, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996;348:1329-36.
7. Diener HC, Cunha L, Forbes C, et al. The ESPS II trial. J Neurol Sci 1996;143:1-13.
8. Coughlin SR, Vu TKH, Wheaton TO. Characterization of a functional thrombin receptor: issues and opportunities. J Clin Invest 1992;89:351-5.
9. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990;322:33-42.
10. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;322:1553-8.
11. EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
12. 2. Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
13. 3. EPILOG investigators. Effect of the glycoprotein IIb/IIIa receptor inhibitor abciximab with lower heparin dosages on ischemic complications of percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
14. The PURSUIT trial investigators. Inhibition of the platelet glycoprotein IIB/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation. N Engl J Med 1998;339:436-43.
15. The PRISM-PLUS investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
16. Feueurstein G, Vasko-Moser J, Koster P. Effects of SB 214857 on in vitro platelet aggregation. Effects of SB 214857 on ex vivo platelet aggregation in dog and monkey. Investigator brochures, SmithKline Beecham.
17. Feueurstein G, Vasko-Moser J, Koster P. Effects of SB 214857 on platelet-dependent coronary thrombosis in the canine "folts model." Effects of SB 214857 on dog coronary thrombosis in LCX wire. Investigator brochures, SmithKline Beecham.
18. 8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
19. 9. Coccheri S, on behalf of the CAPRIE investigators. Distribution of symptomatic atherothrombosis and influence of atherosclerotic disease on risk of secondary ischaemic events: Results from CAPRIE [abstract]. Eur Heart J 1998;19:227.
20. Topol EJ, Byzora TV, Plow EF. Platelet GP IIb/IIIa blockers. Lancet 1999;353:227-31.